Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment (2016)

Peer-Reviewed Study · van Leeuwen FE, Ng AK · December 2, 2016

van Leeuwen FE et al., 2016-12-02: ASH Education review of late effects in Hodgkin lymphoma survivors, separating what radiotherapy and alkylating chemotherapy each contribute to second cancers.

Alkylating agent chemotherapy, especially procarbazine, does not only increase risk of leukemia but also of solid malignancies, in particular, cancers of the lung and GI tract.

Abstract

van Leeuwen FE et al., 2016-12-02: ASH Education review of late effects in Hodgkin lymphoma survivors, separating what radiotherapy and alkylating chemotherapy each contribute to second cancers. Funder/COI: the article states 'The authors declare no competing financial interests' (read from the PMC-deposited author manuscript front matter). Used for the attribution question the claim asks: radiotherapy is associated with a 1.5- to 15-fold increased risk of solid malignancies that persists at least 40 years, while alkylating chemotherapy adds leukaemia and lung/GI solid-tumour risk and gonadotoxic chemotherapy reduces breast-cancer risk. Comparator: none (review). Study type: review.